Clinical Pharmacology: Advances and Applications

Metabolic Syndrome and Cardiovascular Disease

Metabolic syndrome (MetS) is characterized by a constellation of metabolic abnormalities, including obesity (especially central obesity), insulin resistance, hypertension, hypertriglyceridemia, and low levels of high-density lipoprotein cholesterol (HDL-C). Each of these metabolic abnormalities represents an independent risk factor for cardiovascular disease (CVD), and their combination significantly increases the risk of a spectrum of cardiovascular conditions, including microvascular dysfunction, coronary atherosclerosis and calcification, cardiac dysfunction, myocardial infarction, and heart failure.

The MetS is strongly associated with cardiovascular morbidity and mortality. Patients with MetS have a higher risk of developing CVD compared with those without MetS in the next 5–10 years, and the long-term CVD risk is even higher. While advances in understanding the etiology and consequences of the MetS have been made, the underlying pathophysiologic mechanisms that conspire into the full spectrum of the observed MetS-associated cardiovascular pathologies remain insufficiently explained.

This article collection aims to highlight current knowledge pertaining to the pathophysiological mechanisms underlying the MetS-associated cardiovascular entities and the clinical phenotyping of metabolic syndrome, as well as the advanced research in drug development based on experimental or clinical research studies and the therapeutic interventions to reduce the cardiovascular burden of metabolic syndrome.  We welcome submissions (original articles, reviews, or short communications) from clinical, translational, and basic research.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are existing members of the Editorial Board. Please review the journal's Aims and Scope and author submission instructions prior to submitting a manuscript.

Keywords:

• Metabolic Syndrome
• Cardiovascular Disease
• Therapeutic interventions
• Atherosclerosis
• Cardiovascular Risk factors

Please review the journal scope and author submission instructions before submitting a manuscript.

The deadline for submitting manuscripts is 31 December 2025.

Please contact Catherine Teng at catherine.teng@taylorandfrancis.com  with any queries and discount codes regarding this Article Collection.